<DOC>
	<DOCNO>NCT02421367</DOCNO>
	<brief_summary>This study conduct evaluate safety immunogenicity antibody persistence candidate dengue vaccine .</brief_summary>
	<brief_title>Study Varying Injection Schedules TDENV-PIV Vaccine With AS03B Adjuvant Placebo Healthy US Adults</brief_title>
	<detailed_description />
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Subjects must able provide write informed consent . 2 . Subjects must healthy establish medical history clinical examination study entry 3 . Subjects investigator believe comply requirement protocol ( e.g. , completion diary card , return followup visit , etc . ) 4 . Subjects WRAIR CTC must able pas Department Defense ( DoD ) base entry requirement , include possession valid government issue ID card . 5 . Male nonpregnant , nonbreastfeeding female 20 49 year age ( inclusive ) time consent 6 . Female subject nonchildbearing potential ( nonchildbearing potential define one following : tubal ligation least 3 month prior enrollment , hysterectomy , ovariectomy , postmenopausal ) . 7 . Female subject childbearing potential may enrol study , follow apply : Practiced adequate contraception ( see Definition Terms , section 5 ) 30 day prior vaccination Has negative urine pregnancy test day vaccination Agrees continue adequate contraception two month completion vaccination series . 1 . Use investigational nonregistered product ( drug vaccine ) study vaccines/placebo period start 30 day precede first dose study vaccine/placebo and/or plan use study period 2 . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug period start 90 day prior first vaccine/placebo dose ( corticosteroid , mean prednisone &gt; =5mg/day equivalent ; inhale , intranasal topical steroid allow ) 3 . Planned administration administration vaccine/product plan study protocol period start 30 day prior first dose vaccine/placebo 30 day last dose study vaccine/placebo ( routine influenza vaccination allow long administer within 14 day vaccine/placebo , lead study exclusion although report PI ) 4 . History dengue infection dengue illness , history flavivirus vaccination ( e.g. , yellow fever , tickborneencephalitis virus [ TBEV ] , Japanese encephalitis , dengue ) 5 . Planned administration flavivirus vaccine entire study duration 6 . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) 7 . Any confirmed suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) 8 . Family history congenital hereditary immunodeficiency 9 . Autoimmune disease history autoimmune disease 10 . History reaction hypersensitivity likely exacerbate component study vaccine/placebo relate study procedure 11 . Major congenital defect serious chronic illness 12 . History neurological disorder seizures 13 . Diagnosed excessive daytime sleepiness ( unintended sleep episode day present almost daily least 1 month ) narcolepsy ; history narcolepsy subject 's parent , sibling , child 14 . Acute disease and/or fever ( ≥37.5°C/99.5°F oral body temperature ) time enrollment : note subject minor illness mild diarrhea , mild upper respiratory infection , etc. , without fever , may enrol discretion investigator 15 . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test 16 . Administration immunoglobulins and/or blood product period start 90 day precede first dose study vaccine/placebo plan administration study period 17 . Recent history chronic alcohol consumption ( 2 drink per day and/or drug abuse ( base subject report history ) 18 . Pregnant breastfeed female female currently plan become pregnant planning discontinue adequate contraception 19 . A plan move location prohibit participate trial Study End participant 20 . Any condition , opinion investigator , prevents subject participate study . 21 . Subject seropositive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( antiHCV ) , human immunodeficiency virus antibody ( antiHIV ) 22 . Safety laboratory test result screen deem clinically significant Grade 1 deviation normal</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>